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doi:10.1Objective: Epidermal growth factor–loaded gelatin microspheres were tested for potential to accelerate tracheal
allograft reepithelialization.
Methods: Epidermal growth factor–loaded gelatin microspheres were prepared by optimal double-phase emul-
sified condensation polymerization. One hundred age-matched allogeneic mice were randomly allocated to local
administration of 1 mg epidermal growth factor–loaded gelatin microspheres (containing 1 mg epidermal growth
factor), 1 mg gelatin microspheres, 1 mg epidermal growth factor, or nothing (control, all groups n ¼ 25) during
orthotopic transplant of C57BL/6 donor tracheal segments into BALB/c recipients without immunosuppressors.
On days 7, 14, 21, 35, and 52 after transplant, 5 mice per group were killed and evaluated by histologic assessment
and scanning electronic microscopy for reepithelialization and fibrosis of tracheal grafts.
Results: Mean diameter of gelatin microspheres was 107 mm. Microspheres could not be fully degraded until 35
days after transplant in vivo. On days 7, 14, and 21, epithelium score and ratio of lamina propria to tracheal car-
tilage were not statistically different between mice with epidermal growth factor–loaded gelatin microspheres and
other groups. On days 35 and 52, however, epithelium score was higher and ratio of lamina propria to tracheal
cartilage was lower in epidermal growth factor–loaded gelatin microsphere recipients; these mice also had almost
complete differentiation of regenerated epithelium into ciliated columnar epithelium on days 35 and 52, earlier
than in other groups.
Conclusions: Gelatin microspheres act as a functional vector for epidermal growth factor. Sustained local appli-
cation of epidermal growth factor could accelerate reepithelialization of tracheal allografts. (J Thorac Cardiovasc
Surg 2010;140:209-15)Tracheal transplant has for many years been studied as
a means of repairing extensive defects of the trachea.
Although experimental transplants have been performed
on animals and even human patients,1 problems such as graft
rejection, ischemia, and airway obstruction have resulted in
graft failure.
Reepithelialization plays an essential role in viability of
tracheal grafts. Because the epithelium of donor has been
thought to be the primary target of allograft rejection,2 ree-
pithelialization of orthotopic tracheal grafts with recipient-
derived epithelium may be a great help in preventing airway
obliteration and rejection.3-5 Tracheal reepithelialization
takes a long time,6 however, so finding a way to acceleratee Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical
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The Journal of Thoracic and Cathe epithelium regeneration may contribute to the success
of tracheal transplant.
Epidermal growth factor (EGF) could promote epithelial
tissue growth, proliferation, and differentiation.7 It has
been used clinically as an activator to accelerate wound heal-
ing, with satisfactory outcome.8 If EGF could be adminis-
tered to recipients who have received tracheal transplants,
it might be useful in accelerating tracheal reepithelialization.
The half-life of EGF is so short that it has to be applied
several times a day to make ensure functionality, however,
which impedes clinical use. A vector that could load and
continuously release active EGF is therefore needed.
In this study, gelatin microspheres (GMs) were used as
vectors to load EGF (EGF-GMs). EGF was thus applied
locally and persistently to tracheal grafts to observe its effect
on the reepithelialization and fibrosis of the tracheal grafts.E
T
/B
SMATERIALS AND METHODS
Preparation of GMs and Characterization
Examination
The GMs were prepared by optimal double-phase emulsified condensa-
tion polymerization. The gelatin (Sigma, St Louis, Mo) solution (20%, 6
mL, 0.3 ml polysorbate 80 included, analytic reagent; Xi’an Chemical
Co. Xi’an, China) was slowly dropped into preheated liquid paraffin (50
mL, 50C, analytic reagent, Xi’an Chemical) with constant stirring (500rdiovascular Surgery c Volume 140, Number 1 209
Abbreviations and Acronyms
EGF ¼ epidermal growth factor
EGF-GM ¼ epidermal growth factor–loaded gelatin
microsphere
ES ¼ epithelium score
GM ¼ gelatin microsphere
LCR ¼ ratio of lamina propria to tracheal
cartilage
PBS ¼ phosphate-buffered saline solution
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Srpm) for 10 minutes and then quickly cooled down to 0C. Five minutes af-
ter stirring, the formed microspheres were dewatered by adding isopropanol
(10 mL, analytic reagent; Xi’an Chemical). The GMs were washed with iso-
propanol and ethyl ether (analytic reagent; Xi’an Chemical) 3 times to elim-
inate the remaining paraffin. After the ethyl ether had volatilized, the
particles were added into 2.5% glutaraldehyde (4C, analytic reagent;
Xi’an Chemical) aqueous solution for crosslinking. Twenty-four hours later,
2% glycine solution (Sigma) was used to stop the reaction. The GMs were
freeze-dried and preserved for further use.
Preparation of EGF-GMs
The GMs were exposed to cobalt 60 for sterilization. A 25-mg portion of
GMs was immersed into 125 mL phosphate-buffered saline solution (PBS,
pH 7.4) containing 25 mg EGF (PeproTech, Inc, Rocky Hill, NJ) and shaken
for 2 hours under sterile conditions. The GMs loaded with EGF were col-
lected, freeze-dried, and preserved for further use.
Characterization Examination of GMs In Vitro and
In Vivo
The particle size was analyzed with a laser diffraction particles size an-
alyzer (Masterizer 2000; Malvern Instruments Ltd, Malvern, UK). The char-
acteristics of microspheres in vitro were examined by scanning electron
microscopy (S-3400 N; Hitachi, Ltd, Tokyo, Japan). The GMs were
weighed before and after being put into PBS (pH 7.4) for 2 hours. The swell-
ing ratio was derived as the weight of GMs put in PBS for 2 hours divided by
the dry weight of the GMs.
During tracheal transplant, the EGF-GMs or GMs were locally applied.
On days 7, 14, 21, 35, and 52 after tracheal transplant, the residue of the
EGF-GMs or GMs was retrieved when the animals were sacrificed. The deg-
radation of the microspheres in vivo was examined with light microscopy.
Animal Groups
One hundred age-matched allogeneic mice (C57BL/6 as donor and
BALB/c as recipient; Experimental Animal Center, The Fourth Military
Medical University, Xi’an, China) were randomly divided into EGF-GM re-
cipient, GM recipient, EGF recipient, and control groups (n ¼ 25 each). In
the EGF-GM and GM groups, the outer surfaces of tracheal grafts after
transplant, including the anastomoses, were covered circumferentially
with 1 mg EGF-GMs containing 1 mg EGF or 1 mg GMs without EGF.
In the EGF group, the outer surfaces of tracheal grafts after transplant,
including the anastomoses, were soaked circumferentially with 1 mg EGF
diluted with 20 mL PBS). In the control group, nothing was administered
to any graft.
All animals received humane care in compliance with the guidelines of
the Fourth Military Medical University for animal experiments, which met
the standards of the Principles of Laboratory Animal Care formulated by the
National Society for Medical Research and the Guide for the Care and the
Use of Laboratory Animals (www.nap.edu/catalog/5140.html) prepared210 The Journal of Thoracic and Cardiovascular Surgby the Institute of Laboratory Animal Resources and published by the
National Institutes of Health.
Tracheal Grafting Procedures
The tracheal grafting procedure was performed as described by Genden
and colleagues.9 Ketamine (50 mg/kg) and xylazine (10 mg/kg) were in-
jected subcutaneously to anesthetize the mice. The donor mouse tracheal
segment was exposed through an anterior midline neck incision. A 6-ring
circumferential tracheal segment (from the 2nd ring to the 7th ring) was sep-
arated carefully, excised, and put into a sterilized Petri dish with cooled
PBS. The recipient mouse was anesthetized, and the tracheal segment was
exposed through an anterior midline neck incision. A 2-ring incision was
made in the recipient trachea. The donor graft was orthotopically trans-
planted into the recipient tracheal defect and secured with 10-0 nylon inter-
rupted transtracheal sutures. The strap muscles and the skin were sewn up
with 5-0 nylon sutures. After the operation, recipients were placed under
a warming lamp for 3 hours.
Histologic Evaluation
At 7, 14, 21, 35, and 52 days after tracheal transplant, 5 mice from each
group were killed by neck dislocation. The tracheal graft segments were har-
vested, fixed in buffered formalin (4%), and embedded in paraffin. The
grafts were then cut longitudinally into 5-mm sections and stained with he-
matoxylin and eosin. The tracheal epithelium of the donor segment after
transplant was evaluated. The epithelium was assessed in grades as follows:
0, no epithelium; 1, single layer; 2, stratified epithelium; 3, normal ciliated
columnar epithelium. The length of each grade of epithelium was measured
with computer-assisted image technology (Image-Pro Plus 6.0, Media
Cybernetics, Inc, Bethesda, Md). The percentage of each grade of epithe-
lium was calculated. The epithelium score (ES) was then calculated by
taking the percentages represented by each grade, multiplying these by
the respective grade numbers, and adding the results.
The ratio of the lamina propria to the tracheal cartilage (LCR) was used
to assess the degree of fibrosis. The thicknesses of the cartilage and the lam-
ina propria were measured with computer-assisted image technology
(Image-Pro Plus 6.0; Media Cybernetics). The LCR was calculated and
averaged from 5 points for each section.
The histologic evaluation was performed by 2 investigators (L. Gong and
S.J. Zhu) blinded to other data. For each graft, 3 random slides were evalu-
ated for the ES and the LCR.
Scanning Electron Microscopy
The tracheal specimens were harvested and fixed with 3% glutaralde-
hyde in PBS for 24 hours, dried, and gold sprinkled in a vacuum. The spec-
imens were then viewed with a scanning electron microscope (S-3400 N;
Hitachi). The results were objectively assessed by a pathologist for
morphology (X.F. Huang).
Statistical Methods
Results are expressed as mean  SD. Statistical analysis was performed
with the nonparametric Kruskal–Wallis 1-way analysis by ranks. SPSS sta-
tistical software (version 16.0; SPSS, Inc, Chicago, Ill) was used for all data
analysis.RESULTS
Characteristics of EGF-GMs In Vitro and In Vivo
The GMs looked round and regular and were well dis-
persed both in vitro (Figure 1, A) and in vivo (Figure 1,
B–F). The mean diameter was 107 mm, and the swelling ra-
tio was 6.53 1.53. After preservation at 20C to 38C for 2
months, the characteristics of EGF-GMs were unchanged.ery c July 2010
FIGURE 1. Characteristics of epidermal growth factor–loaded gelatin microspheres in vitro were examined with scanning electron microscopy (A), and their
degradation in vivo was examined with light microscopy (B–F, original magnification350). A, Microspheres looked round and regular and were well dis-
persed in vitro. B through D, microspheres had no distinguishable change in structure or appearance in vivo for 21 days after application. B, Day 7; C, day 14;
D, day 21. E, Thirty-five days after application in vivo, most microspheres had lost structure and been degraded. F, Fifty-two days after transplant, micro-
spheres were totally disintegrated.
FIGURE 2. State of tracheal epithelium was evaluated by epithelium
score. Epithelium score of group treated with epidermal growth factor–
loaded gelatin microspheres (EGF-GMs) was higher than scores of groups
treated with epidermal growth factor (EGF), gelatin microspheres (GMs), or
nothing (Control) on days 35 and 52 after transplant. Error bars represent
SD.
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SEGF-GMs had no distinguishable change in structure or ap-
pearance when they were locally applied in vivo for 7, 14, or
21 days (Figure 1, B–D). Thirty-five days after local applica-
tion in vivo, most of the EGF-GMs had lost structure and
been degraded (Figure 1, E). Fifty-two days after transplant,
EGF-GMs had been totally disintegrated (Figure 1, F).
EGF-GM Acceleration of Tracheal Graft Epithelial
Regeneration
Histologic examination and ES calculation were used to
evaluate the state of tracheal epithelialization. As shown in
Figure 2, the ESs of all groups were lowest on day 14
(P< .05), after which they increased gradually. At day 35,
the ES in the EGF-GM group had increased quickly, reach-
ing 2.22  0.09, whereas the ESs of the other groups were
lower (P<.05). Although the ESs of EGF, GM, and control
groups had all increased rapidly at day 52, the ES of EGF-
GMs had reached 2.87  0.14, which was still higher than
those of the other groups (P< .05).
EGF-GMs Acceleration of Tracheal Graft Epithelial
Differentiation
SEM was used to evaluate the differentiation of tracheal
graft epithelium. We found that epithelium in the EGF-
GM group had differentiated into cilia at 35 days after trans-
plant. SEM showed a dense population of ciliated epitheliumThe Journal of Thoracic and Cain the EGF-GM group, whereas sparse populations of
blunted cilia with interspersed mucous cells were seen in
other groups (Figure 3). Fifty-two days after transplant, the
grafts in the EGF-GM group showed intact, well-differenti-
ated, and functional epithelia (Figure 4, A). In the EGF, GM,
and control groups, the ciliated epithelia were still relatively
sparse (Figure 4, B–D).rdiovascular Surgery c Volume 140, Number 1 211
FIGURE 3. Thirty-five days after transplant, scanning electron microscopy showed dense population of ciliated epithelium in epidermal growth factor–
loaded gelatin microsphere group (A), with sparse populations of blunted cilia with interspersed mucous cells in other groups. B, Epidermal growth factor
group; C, gelatin microsphere group; D, control group.
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SEGF-GMs and Tracheal Grafts Fibrosis
The LCR was calculated to evaluate the fibrosis of
tracheal grafts. On days 7, 14, and 21, there was no statistical
difference among the groups in terms of LCR. On days
35 and 52, the LCRs of the EGF-GM group were 1.44 
0.12 and 1.47  0.12, respectively, both of which
values were lower than those of the other groups (P< .05,
Figure 5).
DISCUSSION
Reepithelialization is essential for tracheal grafts. The mu-
rine model of orthotopic tracheal transplantation that was
adopted in this study has proved to be a good model for ex-
perimental study of the reepithelialization of the tracheal
graft.3-6 With murine orthotopic and heterotopic tracheal
transplantation models, it has been proved that immunosup-
pressors can be withdrawn without inciting acute and212 The Journal of Thoracic and Cardiovascular Surgchronic rejection if the donor epithelium is progressively re-
placed by recipient-derived epithelium.4,5 It takes at least
a 48-day period to complete reepithelialization in immuno-
suppressed orthotopic tracheal allografts,6 however, so it is
necessary to find a way to accelerate the epithelial regener-
ation of the tracheal graft.
Many growth factors have been used in animal models to
maintain viability of the tracheal graft.10-18 Basic fibroblast
growth factor and vascular endothelial growth factor have
been studied in tracheal transplants for their strong revascu-
larization effects, and we have also successfully stimulated
cartilage regeneration in tracheal grafts with BMP-2.10
Although vascular endothelial growth factor was of great
benefit to tracheal grafts, it may increase the development
of tracheal luminal occlusion through signaling pathways
mediated by platelet-derived growth factor to recruit mono-
nuclear inflammatory cells.15,16ery c July 2010
FIGURE 4. Fifty-two days after transplant, scanning electron microscopy showed epithelium in epidermal growth factor–loaded gelatin microsphere group
(A) to be intact, well differentiated, and functional, whereas epithelial cells were relatively sparse in other groups. B, Epidermal growth factor group; C, gelatin
microsphere group; D, control group.
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SEGF could promote airway epithelial cell proliferation,
migration, and differentiation through both paracrine and au-
tocrine paths. In 1993, Barrow and associates17 applied aero-
solized EGF plus platelet-derived growth factor to sheep with
acute airway injury, and these growth factors were shown to
be effective in stimulating cell proliferation and accelerating
the repair process. Kim and coworkers18 further demon-
strated in vivo that the effects of EGF on repair of airway
epithelium were concentration dependent and did not depend
on the underlying matrix. Activation of EGF receptor by ac-
tivators such as lower concentrations of lipopolysaccharide
could accelerate wound repair of airway epithelium.19 Aria
and assoicates20 found that the EGF messenger RNA expres-
sion was lower in the allografts than in the isografts in mouse
heterotopic tracheal models. All these studies suggested that
EGF might have a role in the reepithelialization of tracheal
grafts, which is still under investigation.The Journal of Thoracic and CaLike other growth factors, EGF has a short half-life and
requires a continuous exposure to the wounds to facilitate
the regeneration, migration, and proliferation of epithelial
cells. How to apply growth factors during tracheal transplant
is a key problem. Ideally, to resolve this problem, first,
growth factors should be applied persistently without inter-
rupting the vitality of grafts; second, an effective concentra-
tion of growth factors should be maintained around the
tracheal grafts; and third, the method should be simple and
convenient. There have been many methods for administra-
tion of growth factors, such as direct local application,11
nebulization therapy,17 use of biomaterials as vectors,10,12-14
and gene therapy.15 These methods have their own disadvan-
tages, however, and ideal methods of administration still
remain to be achieved.
For topical application of EGF and maintenance of effec-
tive drug concentration in a local area for a long period, werdiovascular Surgery c Volume 140, Number 1 213
FIGURE 5. Subepithelial fibrosis was evaluated by ratio of lamina propria
to tracheal cartilage (LCR). On days 7, 14, and 21 after transplant, there was
no statistically significant difference among groups. Ratio of group treated
with epidermal growth factor–loaded gelatin microspheres (EGF-GMs) was
lower than ratios of groups treated with epidermal growth factor (EGF),
gelatin microspheres (GMs), or nothing (Control) on days 35 and 52. Error
bars represent SD.
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Schose GMs as a vector to load EGF. Gelatin is nontoxic and
biocompatible. It has been used clinically for hemostasis.
Some researchers have been preparing gelatin as a vector
to load biologic agents.14,21,22 Gelatin sheets or gelatin bila-
yer wound dressings containing EGF have been prepared to
provide sustained-released EGF to accelerate wound re-
pair.21 GMs could be made to load biologic agents according
to the expansion characteristic and to release the agents with
microsphere swelling and biodegradation.22 In this study,
we prepared GMs as vectors to load EGF and provide sus-
tained release. When applied locally to the grafts, these
EGF-GMs could be concentrated around the tracheal graft.
When the EGF-GMs were swollen and degraded, the EGF
was persistently released. Our results showed that a dense
population of ciliated epithelium appeared, and the ES was
higher in the EGF-GM group on days 35 and 52, which
suggests that the sustained release of EGF accelerated the
reepithelialization of the tracheal grafts. The application of
immunosuppressive agents could facilitate the regeneration
of epithelium,6,23 which could have distorted our assessment
of the effect of EGF on reepithelialization. To avoid the
influence of immunosuppression, no immunosuppressive
agents were used during this experiment.
EGF-GMs could facilitate airway epithelial regeneration
and differentiation; therefore, they might accelerate fibrosis
at the same time. In our study, we used LCR to evaluate the
degree of fibrosis, because it has been used to evaluate the de-
gree of fibrosis in many studies.6,24 Surprisingly, we found
that fibrosis was not increased by EGF-GMs during the ear-
lier phase after transplant (days 7, 14, and 21 after transplant).
At the same time, the LCR in EGF-GM group was lower than
that of other groups during later phase after transplant (days
35 and 52 after transplant). It is possible that the acceleration
of reepithelialization may affect or even prevent the fibrosis214 The Journal of Thoracic and Cardiovascular Surgto some degree. In our study, the LCR increased to a peak
and maintained that level for a long time. The LCR in the
EGF-GM group had reached a peak by day 14. This peak
was achieved earlier than that in the GM, EGF, and control
groups. At the same time, the ES of the EGF-GM group be-
gan to increase rapidly. Murakawa and colleagues25 reported
that efficient relining with recipient epithelium could prevent
luminal fibrosis in murine tracheal grafts after retransplant
into recipient strain mice. Thus the retardation of the fibrosis
in this study may have resulted from the acceleration of ree-
pithelialization. We also noticed that the LCR pattern in the
EGF-GM group was different from that reported by Genden
and associates.6 Their study showed that the LCR of nonim-
munosuppressed orthotopic allografts increased and reached
a peak by day 28, whereas the LCRs of orthotopic isografts or
immunosuppressed orthotopic allografts were low and re-
mained consistent after transplant. In our study, the LCR of
nonimmunosuppressed orthotopic allografts also increased,
which was concordant with Genden and associates’ study,5
but on days 35 and 52 the LCR of the EGF-GM group was
lower than those of the other groups. Considering the differ-
ence between these 2 studies and the fact that reepithelializa-
tion of orthotopic tracheal grafts with recipient-derived
epithelium may prevent rejection,4,5 we further speculate
that the acceleration of reepithelialization may reduce fibrosis
by reducing rejection.
In conclusion, we successfully prepared GMs loaded with
EGF and applied them locally during tracheal transplant.
Local administration of EGF increased the reepithelialization
of the tracheal grafts. The acceleration of reepithelialization
may reduce fibrosis through reduced immunologic rejection.
Local application of EGF may be an effective method of
accelerating epithelial regeneration of tracheal grafts in
future clinical use.
We thank Dr Hong Wu for her contribution for preparing the
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